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Nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) is a transplantation approach
that enables patients with comorbid conditions to undergo allogeneic HSCT.We investigated the outcome of
patients with reduced renal function as a single comorbidity before HSCT. Thirteen patients with a glomer-
ular filtration rate (GFR) of\60 mL/min/1.73 m2 were matched on sex, age, and type of transplant to 26
controls with normal renal function. All patients received a nonmyeloablative HSCTwith fludarabine and/
or total body irradiation conditioning (TBI). Graft-versus-host disease (GVHD) prophylaxis consisted of my-
cophenolate mofetil and cyclosporine. Data on renal function, cyclosporine dose, cyclosporine trough levels,
hypertension, and GVHD were collected. Of the 13 patients with impaired renal function, 7 patients (54%)
improved or stabilized to a GFR $60 mL/min/1.73 m2 at last follow-up. Four patients (31%) developed
chronic kidney disease stage 3 (GFR\60mL/min/1.73 m2) compared to 3 patients (12%) in the control group
(P5 .039). There was no difference in survival between cases and controls. Furthermore, there were no dif-
ferences in complications after HSCT, and cyclosporine dose and trough levels were similar between cases
and controls. Nonmyeloablative HSCT can be safely offered to patients with mildly reduced renal function.
Cyclosporine can be administered at the same dose as patients without renal dysfunction, as long as cyclo-
sporine trough levels and creatinine are monitored and dose adjustments are made if necessary.
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Chronic kidney disease is a severe complication of
allogeneic hematopoietic stem cell transplantation
(HSCT). An important risk factor for chronic kidney
disease is lower glomerular filtration rate (GFR) before
transplantation [1]. Also in studies on renal function
after solid organ transplantation, impaired renal func-
tion pretransplant predisposes for end-stage renal dis-
ease [2,3]. Moreover, renal dysfunction before HSCT
is 1 of the risk factors of the hematopoietic cell trans-
plantation-specific comorbidity index [4] and the Pre-
transplantation Assessment of Mortality score [5], that
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performed on the outcome of patients with renal dys-
function as a single comorbidity before allogeneic
HSCT.
Nonmyeloablative allogeneic HSCT is a trans-
plantation approach that enables patients with
comorbid conditions to undergo allogeneic HSCT
who otherwise are not suitable for allogeneic myeloa-
blative HSCT [6]. Patients with impaired renal
function can therefore be candidates for nonmyeloa-
blative HSCT. Use of immunosuppressive drugs like
mycophenolate mofetil (MMF) and cyclosporine are
very important to prevent nonengraftment and
graft-versus-host disease (GVHD) [6]. Cyclosporine
is well known for its nephrotoxicity and the major
cause for chronic kidney disease after heart and
lung transplantation [7]. It is not known whether cy-
closporine can be safely used as an immunosuppres-
sive agent in patients with impaired renal function
before HSCT.
The aim of the present study was to assess the out-
come of patients with mildly reduced renal function
before nonmyeloablative HSCT.
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Patients
Between September 1, 2001, and October 1, 2005,
nonmyeloablativeHSCTwas performed in 150 adults,
aged 20-69 years, at the Department of Hematology of
the University Medical Centre Utrecht. Of these pa-
tients, 13 had mildly reduced renal function at baseline
with a GFR of\60 mL/min/1.73 m2 using the simpli-
fied Modification of Diet in Renal Disease (MDRD)
Study prediction equation: GFR 5 186.3  (serum
creatinine)21.154  age20.203  (0.742 for women)
[8]. Two control subjects with normal renal function
for every patient with impaired renal function were
selected from the cohort and matched on sex, age,
and type of transplantation. Patients gave informed
consent and were treated according to clinical proto-
cols approved by the local ethics review board.
Methods
Of the 13 patients with mildly reduced renal func-
tion and 26 controls, data were collected and analyzed
retrospectively using a database and patient records
through December 1, 2007. The following baseline
variables were noted: sex, age, history of autologous
transplantation, history of hypertension (defined as
a blood pressure$140/80 mmHg or receiving antihy-
pertensive medication), diagnosis of hematologic dis-
ease, malignancy risk (low-risk malignancy: patients
with acute leukemia in first complete remission (CR),
chronic myelogenous leukemia (CML) in first chronic
phase and untreated severe aplastic anemia (AA); high-
risk malignancy: all other hematologic diseases), type
of transplant (matched related donor, partially
matched related donor, matched unrelated donor),
and conditioning regimen.
Serum creatinine was noted at the day of HSCT,
monthly during the first year, at 18 months and 24
months and thereafter annually. Renal function was as-
sessed with the simplified MDRD Study prediction
equation at the day of HSCT, monthly during the first
year, at 18 months and 24 months and thereafter annu-
ally. Chronic kidney disease was defined according to
the K/DOQI definition of kidney disease. Stage 3
chronic kidney disease was an estimated GFR \60
mL/min/1.73 m2, stage 4 chronic kidney disease was
a GFR\30 mL/min/1.73 m2, and stage 5 chronic kid-
ney disease a GFR\15 mL/min/1.73 m2 or need for
dialysis using the simplified MDRD Study prediction
equation [8].
Acute renal failure grade 2 was defined as a more
than 2-fold rise in serum creatinine from baseline value
if it occurred within 100 days after HSCT [9].
Nephrotic syndrome was defined as a urinary pro-
tein excretion.3.5 g/24 h and hypoalbuminemia with
plasma levels\3 g/dL.The following variables posttransplantation were
registered: acute and chronic GVHD, (aGVHD,
cGVHD) hypertension, cyclosporine dose the first 3
months, cyclosporine trough levels, duration of cyclo-
sporine use, and survival.
HSCT Procedure
The nonmyeloablative conditioning regimen be-
fore HSCT consisted of fludarabine (30 mg/m2/day
for 3 days) followed by total body irradiation (TBI)
of 200 cGy or TBI of 200cGy alone given in the tan-
dem autologous and allogeneic HSCT. The graft
was infused after TBI on day 0. In recipients of a histo-
compatibility leukocyte antigen (HLA)-matched unre-
lated donor or a single HLA-antigen mismatched
family donor, antithymocyte globulin (ATG) (Rabbit
ATG, Thymoglobulin,Genzyme) was given before
fludarabine was infused, at a dose of 2 mg/kg/day for
4 days. All patients received GVHD prophylaxis orally
with cyclosporine and mycophenolate mofetil (MMF).
Cyclosporine was started on day23 at 4.5 mg/kg twice
daily and continued until day 184 or 1120, followed
by tapering if no GVHD was present. Dose adjust-
ments were made to keep cyclosporine trough levels
between 200 ng/mL and 400 ng/mL.Moreover, cyclo-
sporine dose was lowered when creatinine rise was
caused by cyclosporine, at the discretion of the physi-
cian. MMFmofetil was started 5 hours after graft infu-
sion at 45 mg/kg/day with a maximum dose of 3 g/day
until day 128 or 184, followed by tapering if no
GVHD was present. GVHD was diagnosed according
to the Seattle criteria [10]. aGVHD grade I was treated
with topical corticosteroids. aGVHD grade II or
higher was treated with high-dose systemic corticoste-
roids. Limited cGVHD was not treated, and extensive
cGVHD was treated with cyclosporine, systemic or
topical corticosteroids, MMF, or a combination of
these drugs.
Infection prevention consisted of ciprofloxacin and
fluconazole, given orally, until granulocyte counts ex-
ceeded 500 cell/mL. Cotrimoxazol 480 mg, twice daily,
was given for 15 months and valacyclovir 500 mg,
twice daily, was given for 12 months, both orally.
Statistical Analysis
Continuous variables are displayed as the me-
dian, with range in parentheses. For dichotomous
variables, the frequency of occurrence is given along
with the corresponding percentage. For comparison
of characteristics between patients with or without
renal dysfunction at baseline, chi-square test, or
Fisher’s Exact Test was used to compare propor-
tions, and 2-sided Student’s t-test to compare con-
tinuous outcomes.
Kaplan-Meier survival curves were made for over-
all survival (OS). Curves were compared with log-rank
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considered statistically significant. Analysis was per-
formed using SPSS version 12.0 (SPSS Inc., Chicago
IL).
Table 1. Comparison of Patients with Renal Dysfunction and
Controls
Renal
Dysfunction
n 5 13
Normal Renal
Function
n 5 26
P-
Value
Sex ns
Male 6 (46%) 12 (46%)
Female 7 (54%) 14 (54%)
Age median (range) 58 (37-67) 58.5 (21-65) ns
Type of transplant ns
Matched related donor 10 (77%) 20 (77%)
Partially matched
related donor
0 (0%) 1 (4%)
Matched unrelated donor 3 (23%) 5 (19%)
Mismatch 0 (0%) 3 (12%)
Diagnosis ns
Acute myelogenous leukemia 4 (31%) 6 (23%)
Chronic myelogenous leukemia 0 (0%) 2 (8%)
Severe aplastic anemia 1 (8%) 0 (0%)
Multiple myeloma 1 (8%) 9 (35%)
Non-Hodgkin lymphoma 3 (23%) 4 (15%)
Chronic lymphatic leukemia 2 (15%) 3 (12%)
Myelodysplastic syndrome 2 (15%) 0 (0%)
Myelofibrosis 0 (0%) 1 (4%)
Hodgkin lymphoma 0 (0%) 1 (4%)
Risk ns
Low-risk malignancy 2 (15%) 7 (27%)
High-risk malignancy 11 (85%) 19 (73%)
Previous autologous 1 (8) 10 (39%) ns
Previous hypertension 5 (39%) 9 (35%) ns
Conditioning ns
Fludarabine/TBI 8 (62%) 13 (50%)
Fludarabine/TBI/ATG 4 (31%) 6 (23%)
TBI 1 (8%) 7 (27%)
Renal function at day 0
Creatinine (mmoll/L)
median (range)
117 (91-178) 75 (50-102) <.001
Estimated GFR by
MDRD mL/min/1.73 m2
55 (35-59) 86 (66-124) <.001
Complications ns
Acute renal failure 1 (8%) 8 (31%)
Hypertension within 100 days 5 (39%) 5 (19%)
Acute GVHD grade 0-I 5 (39%) 15 (58%)
Acute GVHD grade II 8 (62%) 8 (31%)
Acute GVHD III-IV 0 (0%) 3 (12%)
Chronic GVHD limited 1 (8%) 2 (8%)
Chronic GVHD extensive 5 (39%) 12 (46%)
Nephrotic syndrome 1 (8%) 1 (4%)
Hypertension at last
follow-up
5 (42%) 9 (35%)
Chronic kidney disease .039
Chronic kidney disease stage 3 4 (31%) 3 (12%)
Chronic kidney disease stage 4 2 (15%) 0 (0%)
Renal function at last follow-up
Creatinine (mmoll/L)
median (range)
109 (66-231) 78.5 (43-115) .014
Estimated GFR by MDRD
mL/min/1.73 m2
60 (26-84) 80.5 (46-151) .002
Outcome
Follow-up in months (range) 33 (8-55) 35(8-62) ns
Survival 10 (77%) 18 (69%) ns
TBI indicates total body irradiation; ATG, antithymocyte globulin; GFR,
glomerular filtration rate; MDRD, Modification of Diet in Renal Disease
Study prediction equation; GVHD, graft-versus-host disease.RESULTS
Characteristics of Patients with Mildly Reduced
Renal Function before HSCT
Of the 150 patients reviewed, 13 patients had
a GFR\60 mL/min/1.73m2 at baseline. Characteris-
tics of this group and their controls are shown in Table
1.
Renal dysfunction was caused by light-chain depo-
sition disease in multiple myeloma (MM) in 1 patient,
and in the rest of the patients there was no established
cause. Treatment with ATG and cyclosporine for se-
vere aplastic anemia (AA) or hypoplastic myelodysplas-
tic syndrome (MDS) might have caused renal
dysfunction in 3 patients. Seven patients (54%) im-
proved or stabilized to a GFR $60 mL/min/1.73 m2
at last follow-up, 4 patients (31%) developed chronic
kidney disease stage 3 (GFR\60 mL/min/1.73 m2),
and 2 patients (15%) had a GFR\30 mL/min/1.73
m2 just before they died from relapse of lymphoma
and chronic lymphocytic leukemia (CLL). A third
patient died with normal renal function from tubercu-
losis.
Comparison of Patients with Renal Dysfunction
and Their Controls
For each patient with renal dysfunction before
HSCT, 2 patients from the cohort with normal renal
function were matched for sex, age, and type of trans-
plant (Table 1). There were no significant differences
in baseline characteristics between between patients
with renal dysfunction and the control group besides
the creatinine and GFR (P\ .001).
In the control group, 2 patients (12%) developed
chronic kidney disease stage 3 (GFR \60 mL/min/
1.73 m2) and no patient developed end-stage renal dis-
ease. This was significantly less than for the patients
with renal dysfunction beforeHSCT (P5 .039). There
was no difference in occurrence of acute renal failure,
hypertension, aGVHD, cGVHD, or nephrotic syn-
drome in patients with renal dysfunction or controls.
Starting dose of cyclosporine was 300 mg (range:
100-500) twice daily in the patients with renal dysfunc-
tion and 350 mg (range: 200-550) twice daily in the
control group. The dose of cyclosporine diminished
in the next 3 months, with no differences between
the groups. Cyclosporine trough levels were similar.
The duration of cyclosporine use was 219 weeks
(range: 111-561) in the patients with renal dysfunction
and 181 weeks (range: 40-1501) in the control group.
This was also not significant different.
Survival
Follow-up was 33 months (range: 8-55) for pa-
tients with renal dysfunction and 35 months (8-62)
for controls. OS was 77% for patients with renal
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icantly different (Figure 1).
DISCUSSION
In this study of 13 patients with mildly reduced re-
nal function before nonmyeloablative allogeneic
HSCT, more than half of patients had improvement
of renal function after HSCT, despite regular treat-
ment with cyclosporine. Furthermore, 31% developed
chronic kidney disease stage 3 (GFR \60 mL/min/
1.73 m2), which occurred in 12% of patients in the
control group with normal renal function pretrans-
plant. No patient progressed to end-stage renal dis-
ease. Also, mortality was not different between the
groups. This suggests that nonmyeloablative HSCT
is a safe option for patients with mildly reduced renal
function before HSCT.
Surprisingly, there was no difference in cyclospor-
ine dose and trough levels between patients with renal
dysfunction and controls. Cyclosporine is metabolized
by the liver and trough levels are not influenced by re-
nal dysfunction [11]. However, one would expect that
patients with renal dysfunction are more susceptible
for rise in serum creatinine and hypertension caused
by cyclosporine, which would lead to adjustment of
the dose by the physician. This was apparently not
the case, because trough levels and cyclosporine dose
were not different between patients with renal
dysfunction and controls, and the incidence of acute
hypertension was similar. It is known from studies in
patients after allogeneic HSCT and heart transplanta-
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Figure 1. Kaplan-Meier survival curve of patients with renal dysfunc-
tion and controls.tion that cyclosporine trough levels often do not
correlate with the occurrence of acute renal failure
[9,12-16]. Nephrotoxicity of cyclosporine seems to
be the result of individual toxic effects of cyclosporine
and not correlated to pretransplant creatinine [15].
This suggests that cyclosporine can be administered
safely in patients with renal dysfunction, as long as
cyclosporine trough levels and creatinine are moni-
tored and dose adjustments will be made similar as in
patients without renal dysfunction.
A limitation of this study is the retrospective nature
and the small sample size. Therefore, it was not possi-
ble to match on all variables; however, the controls
were matched for the most important risk factors for
chronic kidney disease: female sex and older age
[1,17-19].
In conclusion, nonmyeloablative HSCT can be
safely offered to patients with mildly reduced renal
function. Cyclosporine can be administered at the
same dose as patients without renal dysfunction, as
long as cyclosporine trough levels and creatinine are
monitored and dose adjustments are made if necessary.
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